20
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T12838 | SARS-CoV-IN-2 | Others | |
SARS-CoV-IN-2 is an effective SARS-CoV replication inhibitor | |||
T77510 | SARS-CoV-2-IN-46 | SARS-CoV | |
SARS-CoV-2-IN-46 is a SARS-CoV-2 inhibitor. | |||
T77516 | SARS-CoV-2-IN-39 | Antiviral , SARS-CoV | |
SARS-CoV-2-IN-39 is a SARS-CoV-2 inhibitor with an EC50 of 1 μM. SARS-CoV-2-IN-39 has antiviral activity and inhibits SARS-CoV-2 by inhibiting SKP2 protein and stabilizing BECN1. | |||
T60538 | SARS-CoV-2-IN-14 | 3',5-Dichlorosalicylanilide | SARS-CoV |
SARS-CoV-2-IN-14 is a potent and oral inhibitor of SARS-CoV-2 (IC50:0.39 μM), which is an analogue of niclosamide. SARS-CoV-2-IN-14 was more stable than niclosamide in the determination of human plasma and liver S9 enzym... | |||
T77652 | SARS-CoV-2 3CLpro-IN-20 | Antiviral , SARS-CoV | |
SARS-CoV-2 3CLpro-IN-20 is a covalent SARS-CoV-2 3CLpro inhibitor (IC50s: 0.43 μM,).SARS-CoV-2 3CLpro-IN-20 has potential antiviral activity. | |||
T40207 | SARS-CoV-2-IN-7 | ||
SARS-CoV-2-IN-7 demonstrates potent inhibition of viral replication in SARS-CoV-2-infected Vero E6 cells with an IC50 value of 844 nM. | |||
T38942 | SARS-CoV-2-IN-9 | ||
SARS-CoV-2-IN-9 is an inhibitor binding to subsites S1 and S2 in SARS-CoV-2 main protease. | |||
T40340 | SARS-CoV-2-IN-10 | ||
SARS-CoV-2-IN-10 is a powerful and non-toxic inhibitor of SARS-CoV-2 3CL protease, with IC50 and EC50 values of 0.13 nM and 1.03 nM, respectively. The SARS-CoV-2 3C-like protease (3CLpro) is a critical enzyme for viral r... | |||
T40341 | SARS-CoV-2-IN-11 | ||
SARS-CoV-2-IN-11 is a highly potent and non-toxic inhibitor of the 3C-like protease (3CLpro) of SARS-CoV-2, demonstrating IC50 and EC50 values of 0.17 nM and 1.45 nM, respectively. This compound targets the essential vir... | |||
T12836 | SARS-CoV-2-IN-1 | Others | |
SARS-CoV-2-IN-1 is a potent inhibitor of Mpro(SARS-CoV-2 Mpro, SARS-CoV Mpro and MERS-CoV Mpro with IC50s of 0.67, 0.90 and 0.58 μM, respectively). | |||
T60919 | SARS-CoV-2-IN-13 | SARS-CoV | |
SARS-CoV-2-IN-13 (compound 5) is an analogue of niclosamide. SARS-CoV-2-IN-13 is more stable than niclosamide in human plasma and liver S9 enzymes assay. SARS-CoV-2-IN-13 can improve bioavailability and half-life when ad... | |||
T78961 | SARS-CoV-2-IN-38 | SARS-CoV | |
SARS-CoV-2-IN-38, also known as compound 24, is an inhibitor of SARS-CoV-2 that demonstrates favorable oral bioavailability in mice, with an absorption fraction of 39.75% [1]. | |||
T63098 | SARS-CoV-2 Mpro-IN-2 | ||
SARS-CoV-2 MPro-IN-2 is a selective, low cytotoxic, non-covalent Mpro inhibitor with an IC50 value of 0.40 μM. SARS-CoV-2 Mpro-IN-2 showed good anti-SARS-CoV-2 effect with EC50 value of 1.1 μM. SARS-CoV-2 Mpro-IN-2 can b... | |||
T79659 | SARS-CoV-2 3CLpro-IN-16 | SARS-CoV | |
SARS-CoV-2 3CLpro-IN-16 is a covalent SARS-CoV-2 3CLpro inhibitor that inhibits 3CLpro activity and achieves its inhibitory effect by forming a covalent bond with Cys145. | |||
T62834 | SARS-CoV-2-IN-22 | ||
SARS-CoV-2-IN-22 is a SARS-CoV-2 pseudovirus inhibitor (IC50: 16.96 μM). | |||
T64184 | SARS-CoV-2-IN-8 | ||
SARS-CoV-2-IN-8 is a major protease inhibitor of SARS-CoV-2 (IC50: 0.75 μM). | |||
T60556 | SARS-CoV-2-IN-16 | ||
SARS-CoV-2-IN-16 (Compound 12) is a potent inhibitor of SARS-CoV-2 nucleocapsid protein (NPro) with potent antiviral activity (EC50 = 3.69 μM). SARS-CoV-2-IN-16 binds to NPro with a low Kd value of 7.82 μM, which suggest... | |||
T60962 | SARS-CoV-2-IN-18 | ||
SARS-CoV-2-IN-18 (Compound 26) is a potent inhibitor of SARS-CoV-2 3C-like protease (IC50 = 45 nM) [1]. | |||
T79243 | SARS-CoV-2-IN-43 | SARS-CoV | |
Compound 8h, also known as SARS-CoV-2-IN-43, is a powerful inhibitor effective in obstructing the replication of SARS-CoV-2, exhibiting significant antiviral activity [1]. | |||
T61613 | SARS-CoV-2-IN-17 | ||
SARS-CoV-2-IN-17 (Compound 16) is a highly effective inhibitor of SARS-CoV-2 nucleocapsid protein (NPro). It demonstrates potent anti-viral activity, with an EC50 value of 2.18 μM. Furthermore, SARS-CoV-2-IN-17 binds to ... |